Boston Scientific, Inc. (BSX) appears in good shape, with its shares rallying 4.6% since the fourth-quarter earnings release. The company is gaining from strong worldwide demand for its GI and pulmonary treatment options. The traction in Europe for its next-generation WATCHMAN FLX and a contribution from accretive acquisitions are important growth drivers.The Zacks Rank #2 (Buy) stock has moved up 4.6% since the last earnings release compared with the industry’s rise of 1%. The Medical sector has increased ...

Boston Scientific (BSX) recently announced the completion of the first commercial cases in the United States with its FDA-approved Farapulse Pulsed Field Ablation (PFA) system.In January 2024, the company received the FDA clearance for the Farapulse PFA System. This made Boston Scientific the second company to have received an FDA nod for PFA for treating AFib.With the approval, Farapulse can be used to treat drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation in the isolation of pulmonar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2695240 (State or other jurisdiction of incorporation or organization) (I.R.S. ...

Boston Scientific Corporation (BSX) is gaining from strength across target markets. Strong worldwide demand for its GI and pulmonary treatment options, traction in Europe for its next-generation WATCHMAN FLX and contribution from accretive acquisitions are important drivers. However, unfavorable currency movements and stiff competition are a concern.In the past year, this Zacks Rank #2 (Buy) stock has gained 37.1% compared with a 5.5% fall of the industry and a 23.6% rise of the S&P 500.The renowned manufac ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks R ...

Boston Scientific, Inc. (BSX) recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation. The system represents a unique new alternative to standard-of-care thermal ablation treatment.Addressing the vast population living with paroxysmal atrial fibrillation (AF), the approval offers an incredible opportunity t ...

Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 55 cents for the fourth quarter of 2023, up 22.2% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.8% and also exceeded the company’s adjusted earnings per share guidance range of 49-52 cents.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others.Reported EPS for the fourth quarter ...

Boston Scientific Corporation (NYSE:BSX) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Jon Monson - Global Controller and Chief Accounting Officer Janarthanan Sathananthan - Chief Medical Officer Conference Call Participants Robert ...

For the quarter ended December 2023, Boston Scientific (BSX) reported revenue of $3.73 billion, up 14.9% over the same period last year. EPS came in at $0.55, compared to $0.45 in the year-ago quarter.The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $3.59 billion. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Boston Scientific Corp.’s stock BSX, +0.18% jumped 5.8% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024. The Marlborough, Mass.-based medical technology company posted net income of $504 million, or 34 cents a share, for the quarter, up from $126 million, or 9 cents a share, in the year-earlier period. Excluding special items, the company had EPS of 55 cents, ahead of the 51 cent FactSet consensus. Sales rose 14.9% to $3.725 billion, well ahead of the $3 ...